Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?
VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.
Overview
The Invesco Pharmaceuticals ETF (NYSEMKT:PJP) provides broader pharmaceutical exposure and a higher dividend yield, while the VanEck Biotech ETF (NASDAQ:BBH) offers a more concentrated biotechnology play with a lower expense ratio.
Healthcare investors often choose between high-growth biotechnology and established pharmaceutical giants. These two funds offer targeted exposure to these sub-sectors. While the VanEck fund focuses on companies at the cutting edge of genetic research, the Invesco fund tracks established entities involved in the broader manufacturing and distribution of traditional drugs.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the end of trading on Aug. 20, 2026.
Source
Originally published at www.fool.com.